The present invention relates to compounds that are able to inhibt functional proteins of COVID-19 virus, SARS-Cov-2.

A suxamethonium pharmaceutical composition including suxamethonium chloride and a succinic acid buffer. Also, a prefilled syringe thereof and a process of sterilizing the suxamethonium prefilled syringe. The composition and the prefilled syringe are useful as ready-to-use formulations, especially in emergency conditions, and present long shelf lives, even at room temperature.

A suxamethonium pharmaceutical composition including suxamethonium chloride and a succinic acid buffer. Also, a prefilled syringe thereof and a process of sterilizing the suxamethonium prefilled syringe. The composition and the prefilled syringe are useful as ready-to-use formulations, especially in emergency conditions, and present long shelf lives, even at room temperature.

The present invention relates to compositions and methods for potentiating glutathione enhancement for use in brain health. In particular, the compositions and methods of the invention are beneficial for use in subjects in need of increasing motivational performance and/or mental energy, functions that may be decreased upon stress and anxiety.

Described herein are compositions and methods for treating inflammation, and inflammation-related conditions, using fumarate or fumarate analogs or inhibitors of fumarate hydratase (FH).

Described herein are compositions and methods for treating inflammation, and inflammation-related conditions, using fumarate or fumarate analogs or inhibitors of fumarate hydratase (FH).

Methods for the use of prodrugs of itaconic acid and 1- and 4-methyl itaconic acid for inducing hair growth and treating an inflammatory, or immune activation (adaptive or innate), skin condition or other condition associated with hair loss are disclosed.

Methods for the use of prodrugs of itaconic acid and 1- and 4-methyl itaconic acid for inducing hair growth and treating an inflammatory, or immune activation (adaptive or innate), skin condition or other condition associated with hair loss are disclosed.

Methods for the use of prodrugs of itaconic acid and 1- and 4-methyl itaconic acid for inducing hair growth and treating an inflammatory, or immune activation (adaptive or innate), skin condition or other condition associated with hair loss are disclosed.

Disclosed herein are methods for (a) inhibiting, reducing, slowing, or preventing, the aging of a subject, (b) for treating, inhibiting, reducing, or preventing an age-related disease in the subject, and/or (c) for increasing the lifespan of the subject which comprise administering to the subject one or more glutarate compounds, such as α-ketoglutate, and/or one or more glutamate compounds, such as 2-hydroxypentanedioate, and compositions thereof.